BRPI0511754A - uso de um composto ou sais ou solvatos do mesmo - Google Patents

uso de um composto ou sais ou solvatos do mesmo

Info

Publication number
BRPI0511754A
BRPI0511754A BRPI0511754-2A BRPI0511754A BRPI0511754A BR PI0511754 A BRPI0511754 A BR PI0511754A BR PI0511754 A BRPI0511754 A BR PI0511754A BR PI0511754 A BRPI0511754 A BR PI0511754A
Authority
BR
Brazil
Prior art keywords
solvates
salts
compound
relates
quinazolinamines
Prior art date
Application number
BRPI0511754-2A
Other languages
English (en)
Inventor
Mark S Berger
Iman El-Hariry
Tona Morgan Gilmer
Arundathy Nirmalini Pandite
David Rusnak
Neil L Spector
Original Assignee
Smithkline Beechman Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beechman Cork Ltd filed Critical Smithkline Beechman Cork Ltd
Publication of BRPI0511754A publication Critical patent/BRPI0511754A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE UM COMPOSTO OU SAIS OU SOLVATOS DO MESMO A presente invenção diz respeito a um método de tratar o câncer em um mamífero pela administração de 4-quinazolinaminas e composições farmacêuticas que as contenham. Em particular, o método diz respeito a um método de tratar cânceres que são mediados pelas tirosina quinases EGER e/ou erbB2 pela administração de N-{3-cloro-4-¢(3-fluorobenzil)óxi!fenil}-6- ¢5 -({¢2-(metanossulfonil)etil!amino}metil)-2-furil!-4-quinazolinamina e sais e solvatos do mesmo.
BRPI0511754-2A 2004-06-03 2005-06-01 uso de um composto ou sais ou solvatos do mesmo BRPI0511754A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57682504P 2004-06-03 2004-06-03
US60679004P 2004-09-02 2004-09-02
PCT/US2005/019053 WO2005120504A2 (en) 2004-06-03 2005-06-01 Cancer treatment method

Publications (1)

Publication Number Publication Date
BRPI0511754A true BRPI0511754A (pt) 2008-01-02

Family

ID=35503647

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511754-2A BRPI0511754A (pt) 2004-06-03 2005-06-01 uso de um composto ou sais ou solvatos do mesmo

Country Status (14)

Country Link
US (1) US20100063074A1 (pt)
EP (1) EP1768963A4 (pt)
JP (1) JP2008501690A (pt)
KR (1) KR20070030240A (pt)
AU (1) AU2005251722B2 (pt)
BR (1) BRPI0511754A (pt)
CA (1) CA2569132A1 (pt)
IL (1) IL179359A0 (pt)
MA (1) MA28691B1 (pt)
MX (1) MXPA06013635A (pt)
NO (1) NO20066077L (pt)
NZ (1) NZ551622A (pt)
RU (1) RU2006142420A (pt)
WO (1) WO2005120504A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501572A (ja) * 2006-08-22 2010-01-21 コンサート ファーマシューティカルズ インコーポレイテッド ４−アミノキナゾリン誘導体およびその使用方法
WO2009137714A2 (en) 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010017387A2 (en) * 2008-08-06 2010-02-11 Teva Pharmaceutical Industries Ltd. Lapatinib intermediates
EP2158912A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158913A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP3400943B1 (en) 2012-03-23 2020-12-02 Array Biopharma, Inc. Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
BR112019022280A2 (pt) 2017-04-28 2020-05-19 Seattle Genetics Inc tratamento de cânceres de her2 positivo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
AU2001273071B2 (en) * 2000-06-30 2005-09-08 Glaxo Group Limited Quinazoline ditosylate salt compounds
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
JP2004002210A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
JP2004002211A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
BR0309226A (pt) * 2002-04-16 2005-02-09 Astrazeneca Ab Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável
EP1810034A4 (en) * 2002-06-19 2008-06-25 Smithkline Beecham Corp PREDICTIVE MARKERS IN CANCER THERAPY
BR0313197A (pt) * 2002-08-02 2005-08-09 Immunogen Inc Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico
JP2004144680A (ja) * 2002-10-25 2004-05-20 Nanko Kyo 細胞増殖を制御する物質のスクリーニング方法、及びＳｐ１分子等をヌクレオリン（ｎｕｃｌｅｏｌｉｎ）分子から解離させる物質のスクリーニング方法

Also Published As

Publication number Publication date
EP1768963A4 (en) 2009-06-10
AU2005251722A1 (en) 2005-12-22
AU2005251722B2 (en) 2009-11-12
EP1768963A2 (en) 2007-04-04
KR20070030240A (ko) 2007-03-15
CA2569132A1 (en) 2005-12-22
RU2006142420A (ru) 2008-07-20
JP2008501690A (ja) 2008-01-24
NZ551622A (en) 2010-01-29
WO2005120504A3 (en) 2006-02-23
MXPA06013635A (es) 2007-02-28
WO2005120504A2 (en) 2005-12-22
US20100063074A1 (en) 2010-03-11
IL179359A0 (en) 2007-03-08
NO20066077L (no) 2007-01-31
MA28691B1 (fr) 2007-06-01

Similar Documents

Publication Publication Date Title
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
CY1111599T1 (el) Αναστολεις κινασης θειενοπυριδινης και φουροπυριδινης
MY169272A (en) Her2 antibody composition
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
CY1116191T1 (el) Παραγωγα πυριδαζινονης
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
CY1115925T1 (el) Παραγωγα πυριδαζινονης
LTC1934174I2 (lt) Azetinidai kaip MEK inhibitoriai, skirti proliferacinių ligų gydymui
BRPI0516968A (pt) composto, composição, e, método de tratamento de distúrbio hiperproliferativo
CY1116015T1 (el) Καινοφανεις ενωσεις και μεθοδοι για θεραπεια
ATE554087T1 (de) Neue kinaseinhibitoren
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
PE20090365A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
BRPI0518794A2 (pt) composto, composiÇço, mÉtodo de tratamento de distérbio hiperproliferativo, e, biblioteca combinatorial
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
EA200901611A1 (ru) Производные 2-оксо-3-бензил-бензоксазол-2-она и родственные соединения в качестве ингибиторов мет киназы для лечения опухолей
BR0211926A (pt) agentes para realçar a resposta imune
CY1111197T1 (el) Tριαζολες χρησιμες ως αναστολεις πρετεϊνικων κινασων
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
CY1108061T1 (el) Παραγωγα κιναζολινης ως src αναστολεις κινασης τυροσινης
CY1113698T1 (el) Παραγωγα πυριδαζινονης
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.